WHO has issued a statement regarding a planned hepatitis B birth dose vaccine trial in Guinea-Bissau. The statement discusses the rationale, objectives, and potential benefits of the trial, while acknowledging the need for further research to address uncertainties around the optimal timing and delivery of the hepatitis B vaccine in this context.
Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau
Informational, non-clinical synthesis informed by published research. Not a clinical guideline or medical advice. May contain errors or editorial interpretation. Consult the original source and your physician.
